Skip to main navigation
skip to Main Content
Codexis
  • Why Codexis
    • Company
      • About Us
      • Why Codexis
      • Partners
      • Leadership
      • Board of Directors
    • Industries
      • Pharmaceuticals
      • Biotherapeutics
      • Food & Beverage
      • Molecular Diagnostics
    • Resources
      • Scientific Showcase
      • Awards & Recognition
      • News
      • Events
  • What You Need
    • Protein Engineering
    • CodeEvolver® Licensing
    • Scale-up and Supply
    • Screening Kits
  • Contact
  • Careers
  • Investors
Open Mobile Menu
Press Releases SEC Filings Stock Information Events / Webcasts Corporate Governance Analysts FAQ Contacts

Investors

Press Release

Codexis to Hold 2017 Fourth Quarter and Full Year Conference Call on March 8

March 1, 2018
PDF Version

REDWOOD CITY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2017 financial results after market close on Thursday, March 8, 2018. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. 

Live Call: U.S. 855 890 8665
  International 720 634 2938
  Passcode 3990608
     
Live Webcast: Codexis IR Website 
  The webcast will be archived for 30 days.
     
Replay: U.S. 855 859 2056
  International 404 537 3406
  Passcode 3990608
  The replay will be available for 48 hours
   

About Codexis, Inc.

Codexis, Inc. is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of high-value industrial applications, including as biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables significant improvements in protein performance meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial scale implementations of biocatalytic processes. For more information, see www.codexis.com.

CONTACTS

Investors
LHA Investor Relations
Jody Cain, 310 691 7100
jcain@lhai.com

Primary Logo

Source: Codexis, Inc.

In This Section
  • Investors
  • Press Releases
  • SEC Filings
  • Stock Information
  • Events / Webcasts
  • Corporate Governance
  • Analysts
  • FAQ
  • Contacts
Recent News
  • February 14, 2019
    Summary ToggleCodexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
  • February 6, 2019
    Summary ToggleCodexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
  • February 4, 2019
    Summary ToggleCodexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
Featured Documents
Corporate Presentation 3 MB
Codexis Pipeline Snapshot 1.1 MB

Sign up for E-mail Alerts

 
Contact Investors Careers

© 2019 Codexis, Inc. All rights reserved. Privacy Policy Site Credits

Back To Top